Panelists discuss how employers optimize biosimilar uptake through strategic formulary design, financial incentives, and provider education, enabling health care systems to achieve substantial cost savings while maintaining high-quality patient care.
Video content above is prompted by the following:
Missed Opportunities for Salpingectomy Highlight Gaps in Ovarian Cancer Prevention
August 27th 2025Many patients later diagnosed with high-grade serous cancer had prior surgical or genetic testing opportunities that could have reduced their ovarian cancer risk, underscoring the need to expand opportunistic salpingectomy and preventive strategies.
Read More
MG Symptoms PRO Highlights Rozanolixizumab’s Impact on Fatigue, Weakness
August 22nd 2025The humanized IgG4 monoclonal antibody was first approved for myasthenia gravis in the US in 2023, with approvals in Japan and the European Union following later that year and 2025, respectively.
Read More